Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$88.55	-2.38%	515.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$88.55	-2.4%	515.77K
3
4
5
6

DNTH

Get Dianthus Therapeutics, Inc. Data in Excel

Get Dianthus Therapeutics, Inc. Data in Excel